Showing 2121-2130 of 8831 results for "".
Breaking a Sweat: Treating Hyperhidrosis in the COVID-19 Era
https://practicaldermatology.com/series/dermatology-dispatches/breaking-a-sweat-treating-hyperhidrosis-in-the-covid-19-era/19767/Hyperhidrosis patients can be evaluated with telemedicine, says Neal Bhatia, MD. It’s important that these individuals have adequate supplies of their medication for the duration of any stay-at-home orders. In addition, dermatologists should try to distinguish between anxiety-induced sweating and prRed Light vs Blue Light Therapy
https://practicaldermatology.com/series/pdt-in-practice/red-light-vs-blue-light-therapy/26993/Dr. Hamza D. Bhatti, a board-certified dermatologist and dually accredited fellowship-trained Mohs micrographic surgeon and cosmetic dermatologic surgeon, discusses the differences between red light and blue light photodynamic therapy (PDT), the advantages of each, and some off-label uses of PDT.Exosomes 101
https://practicaldermatology.com/conferences/scale-2023/exosomes-101/20192/Exosomes are today's hottest skincare ingredient, and Glynis Ablon, MD, gives viewers the scoop on how and when to use them.Skin Cancer Perceptions, Cimzia for Psoriasis, Eczema and CV Risk
https://practicaldermatology.com/topics/psoriasis/dermwire-tv-skin-cancer-perceptions-cimzia-for-psoriasis-eczema-and-cv-risk/18301/A new national survey, Skin Cancer In America 2018, conducted by Health Union, explores perceptions of patients with skin cancer. Cimzia (certolizumab pegol, UCB) has received FDA approval for treatment of adults with moderate to severe plaque psoriasis. Cimzia is the first Fc-free, PEGylated anti TConnective Tissue Disorders Update 2025: Dr. Vleugels
https://practicaldermatology.com/programs/practical-dermatology/connective-tissue-disorders-update-2025-dr-vleugels/32673/Ruth Ann Vleugels, MD, PhD, recaps her presentation, "Connective Tissue Disorders Update 2025" at Maui Derm 2025. Dr. Vleugels discussed a new therapeutic for systemic lupus, a new FDA-approved option for dermatomyositis, JAK inhibitors, and more.The Impact of Clascoterone Topical Cream, 1%
https://practicaldermatology.com/issues/april-2025/the-impact-of-clascoterone-topical-cream-1/35605/Clascoterone topical cream, 1% (Winlevi, Sun Pharmaceuticals, Inc.) approved by the US Food and Drug Administration (FDA) in 2020 as the first novel drug introduced for the treatment of acne vulgaris since 1982, is indicated in the US for patients 12 years of age and older.The View from Under the Hood
https://practicaldermatology.com/issues/january-february-2025/the-view-from-under-the-hood/32967/As 2025 brings new approvals for treatments for hidradenitis suppurativa, chronic spontaneous urticaria, psoriatic arthritis, and several other diseases that need answers, this is a good time for us to remember that the most important approach to treatment starts with the right diagnosis.Psoriasis Update 2025: Dr. Gelfand
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/psoriasis-update-2025-dr-gelfand/32672/Joel Gelfand, MD, MSCE, discusses highlights from the "Psoriasis Update 2025" panel at Maui Derm 2025, including the potential for combining TNF inhibitors with IL-23 inhibitors; home phototherapy; and the possibility of GLP-1 agonists lowering the severity of psoriatic disease.We've Got to Do Better
https://practicaldermatology.com/topics/practice-management/weve-got-to-do-better/20018/As a specialty, dermatology is doing more to address issues of diversity, equity, and inclusion, but Jeanine Downie, MD says there is more to do. She discusses issues such as dealing with microaggressions, increasing diversity in the workforce, and seeing the humanity in every patient.Elucidating the Inflammatory Cascade May Help to Turn Out the Lights in Psoriasis
https://practicaldermatology.com/topics/psoriasis/elucidating-the-inflammatory-cascade-may-help-to-turn-out-the-lights-in-psoriasis/19943/Understanding the science behind psoriasis pathogenesis has raised the bar in the management of disease. Watch the video to visualize the patient journey, their unmet needs, and aim to set higher standards in the psoriasis landscape.